Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | TOTAL Therapy 7: high response rates in high risk NDMM to daratumumab

The TOTAL Therapy (TT) approach has significantly improved the outcome of multiple myeloma (MM) by combining new drugs with a regimen that comprises induction, tandem autologous stem cell transplantation (ASCT), consolidation and maintenance. In the TT7 study, daratumumab was induced during all phases of therapy for high risk newly diagnosed MM, including immune consolidation early post-ASCT. Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, discusses the early results of TT7, pointing to increased response rates of newly diagnosed high risk MM to daratumumab. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.